Sanofi (NASDAQ:SNY) Sets New 12-Month Low – Time to Sell?

Sanofi (NASDAQ:SNY)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The company traded as low as $39.18 and last traded at $39.2550, with a volume of 2,823,615 shares trading hands. The stock had previously closed at $39.74.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SNY shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Wolfe Research began coverage on shares of Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating for the company. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Stock Performance

The company’s 50 day moving average price is $42.79 and its 200-day moving average price is $43.86. The stock has a market cap of $97.60 billion, a P/E ratio of 21.09, a price-to-earnings-growth ratio of 1.20 and a beta of 0.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.24 earnings per share. Equities analysts forecast that Sanofi will post 5.00 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Bank of America Corp DE raised its holdings in shares of Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after acquiring an additional 940,342 shares during the period. Royal Bank of Canada increased its position in shares of Sanofi by 17.5% during the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after purchasing an additional 470,882 shares during the last quarter. Regal Partners Ltd raised its holdings in Sanofi by 33.2% in the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock valued at $122,639,000 after buying an additional 633,782 shares during the period. Manning & Napier Advisors LLC lifted its position in Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock valued at $57,542,000 after buying an additional 1,194,141 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Sanofi by 2.4% during the first quarter. First Trust Advisors LP now owns 767,835 shares of the company’s stock worth $36,994,000 after buying an additional 17,880 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.